Atendol, a small molecule drug, falls under the ambit of the β1-adrenergic receptor antagonists class. Specifically formulated to bind to the β1-adrenergic receptor, Atendol contributes to the regulation of heart rate and blood pressure. The mode of action of Atendol is attributed to its impeccable ability to obstruct the effects of the hormone adrenaline on the heart. Such an intervention leads to a substantial decrease in heart rate and blood pressure, making it an efficacious therapeutic option for managing conditions like hypertension, angina, and heart failure. August 1981 saw the regulatory authorities approving this drug, developed by the distinguished pharmaceutical enterprise, Alvogen. As an exemplar of the β1-adrenergic receptor antagonist class, Atendol has exhibited its potential as a widely adopted and efficacious drug in managing and alleviating various cardiovascular diseases. Click on the image below to begin the exploration journey of Atendol through the Synapse database!
You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!